

# Eric William

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6620668/eric-william-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91  
papers

1,013  
citations

14  
h-index

30  
g-index

93  
ext. papers

1,350  
ext. citations

2.9  
avg, IF

3.61  
L-index

#	Paper	IF	Citations
91	Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO210196† <sup>2</sup>	2.2	5
90	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS398-TPS398	2.2	3
89	Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 224-224	2.2	1
88	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, 84-97	1.2	1
87	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , <b>2021</b> , 5, 21-29	0.6	0
86	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , <b>2021</b> , 80, 693-700	10.2	10
85	Primary Mediastinal Germ Cell Tumors-The University of Western Ontario Experience. <i>Current Oncology</i> , <b>2020</b> , 28, 78-85	2.8	1
84	Near Miss or Standard of Care? Screening for Cancer Patients Receiving Fluorouracil. <i>Current Oncology</i> , <b>2020</b> , 28, 94-97	2.8	1
83	Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer. <i>Oral Oncology</i> , <b>2020</b> , 101, 104529	4.4	4
82	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1751-1758	13.4	9
81	Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E154-E158	1.2	12
80	Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1349-1359 <sup>21.7</sup>	21.7	164
79	Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (DPYD) genotype testing for fluoropyrimidine-based chemotherapy on adverse events and hospital costs.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3028-3028	2.2	1
78	Successful treatment of nasopharyngeal cancer using radiotherapy with concurrent cetuximab in a patient with Charcot-Marie-Tooth disease. <i>BMJ Case Reports</i> , <b>2019</b> , 12,	0.9	0
77	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. <i>Oral Oncology</i> , <b>2019</b> , 89, 72-78	4.4	16
76	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , <b>2019</b> , 108, 69-77	7.5	20
75	The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study. <i>PharmacoEconomics - Open</i> , <b>2018</b> , 2, 255-270	2.1	5

74	Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 193-193	2.2	2
73	Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 273-273	2.2	4
72	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. <i>Oncotarget</i> , <b>2018</b> , 9, 8155-8164	3.3	8
71	High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. <i>Oncotarget</i> , <b>2018</b> , 9, 26064-26071	3.3	11
70	The Clinical Significance of Occult Gastrointestinal Primary Tumours in Metastatic Cancer: A Population Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 183-194	5.2	2
69	Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , <b>2018</b> , 23, 271-282	3.7	8
68	Late Relapse of Ovarian Germ Cell Tumour. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2018</b> , 40, 1329-1332	4.3	2
67	Editorial Comment. <i>Journal of Urology</i> , <b>2018</b> , 200, 351-352	2.5	
66	Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 12, E365-E372	1.2	4
65	Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). <i>European Journal of Cancer</i> , <b>2017</b> , 72, 192-199	7.5	14
64	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , <b>2017</b> , 35, 1729-1736	4	7
63	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2017</b> , 3, 220-226	13.4	48
62	Chronic Oxaliplatin-Based Chemotherapy in a Primary Ampullary Adenocarcinoma Patient without Significant Peripheral Neuropathy: Case Report and Literature Review. <i>Case Reports in Oncology</i> , <b>2017</b> , 10, 577-581	1	2
61	Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, E449-E450	1.2	3
60	Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, E64-E65	1.2	2
59	Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , <b>2017</b> , 11, 24-30	1.2	5
58	Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1952-1964	2.2	35
57	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4514-4514	2.2	2

56	A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5021-5021	2.2	1
55	Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 71512-71519	3.3	18
54	Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 260-260	2.2	
53	Utility of annual screening serum testosterone level in men on surveillance for clinical stage I testicular cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 144-144	2.2	
52	Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6013-6013	2.2	0
51	Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, 102-9	1.2	11
50	Pre-treatment serum folate levels and toxicity in colorectal cancer patients treated with 5-fluorouracil and folic acid.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 755-755	2.2	
49	Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. <i>Oncologist</i> , <b>2015</b> , 20, 1351-2	5.7	13
48	Do retroperitoneal extragonadal germ cell tumours exist?. <i>Canadian Urological Association Journal</i> , <b>2015</b> , 9, 381-4	1.2	6
47	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4555-4555	2.2	2
46	Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN):	2.2	15
45	IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 279-279	2.2	2
44	A retrospective analysis of clinical factors influencing response to treatment with cabazitaxel in patients with metastatic castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 281-281	2.2	
43	Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). NCI Clinical Trials Group HN-6 (NCT00820240).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 281-281	2.2	
42	Application of a policy framework for the public funding of drugs for rare diseases. <i>Journal of General Internal Medicine</i> , <b>2014</b> , 29 Suppl 3, S774-9	4	14
41	Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 1073-9	14.4	6
40	Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3436-48	2.2	167
39	ECF chemotherapy for liver metastases due to castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , <b>2014</b> , 8, 353-7	1.2	2

38	Toward a functional definition of a "rare disease" for regulatory authorities and funding agencies. <i>Value in Health</i> , <b>2014</b> , 17, 757-61	3.3	15
37	Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , <b>2014</b> , 22, 391-5	5.3	79
36	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5051-5051	2.2	2
35	Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5062-5062	2.2	3
34	Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6041-6041	2.2	4
33	Vorinostat (VOR) and capecitabine (CAP) in recurrent and/or metastatic squamous cell carcinoma of head and neck (RMHNSCC): A study of the Princess Margaret Phase II Consortium.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e17001-e17001	2.2	1
32	Bone metastases in germ cell tumors: Results from an international data base.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4559-4559	2.2	
31	Tamoxifen-associated hot flash severity and its correlation with endoxifen concentration.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e20657-e20657	2.2	
30	Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11016-11016	2.2	1
29	Identification of the occult tumor in cancer of unknown primary (CUP): A priority based on histology.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1605-1605	2.2	2
28	NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5042-5042	2.2	3
27	Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6041-6041	2.2	5
26	Cabazitaxel in docetaxel-pretreated metastatic castration resistant prostate cancer (mCRPC): Canadian experience.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16082-e16082	2.2	1
25	Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 153-153	2.2	1
24	Evaluating the hidden biology of cancer of unknown primary (CUP) in comparison to known metastatic disease.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e12549-e12549	2.2	
23	Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16088-e16088	2.2	
22	Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5504-5504	2.2	11
21	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN-6).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TP65100-TP65100	2.2	1

20	Temsirolimus (TEM) maintenance therapy after response of castration-resistant prostate cancer (CRPC) to docetaxel (TAX).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e15177-e15177	2.2	
19	Large retroperitoneal lymph nodes (RPLN) as a novel risk factor for venous thromboembolism (VTE) in germ cell tumor (GCT) patients (pts) receiving first-line chemotherapy (chemo).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4535-4535	2.2	
18	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2012</b> , 19, 6232-7	0.8	
17	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2012</b> , 19, 6587-91	0.8	1
16	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2011</b> , 18, 5650-6	0.8	1
15	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2011</b> , 18, 5849-55	0.8	1
14	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2010</b> , 17, 5141-7	0.8	
13	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2010</b> , 17, 5239-44	0.8	
12	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2010</b> , 17, 5338-42	0.8	
11	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2010</b> , 17, 5419-23	0.8	
10	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2009</b> , 16, 4617-23	0.8	
9	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2009</b> , 16, 4875-81	0.8	
8	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2008</b> , 15, 3942-9	0.8	
7	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2008</b> , 15, 4034-42	0.8	
6	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2008</b> , 15, 4284-90	0.8	
5	Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. <i>Head and Neck</i> , <b>2007</b> , 29, 38-46	4.2	64
4	Open clinical uro-oncology trials in Canada. <i>Canadian Journal of Urology</i> , <b>2007</b> , 14, 3716-22	0.8	
3	Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care@ Genitourinary Cancer Disease Site Group. <i>BMC Cancer</i> , <b>2006</b> , 6, 112	4.8	39

2	Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 159-67	4.3	106
1	A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer. <i>Canadian Journal of Urology</i> , <b>2004</b> , 11, 2445-9	0.8	3